Midwest Trust Co Invests $443,000 in Axon Enterprise, Inc $AXON

Midwest Trust Co acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 535 shares of the biotechnology company’s stock, valued at approximately $443,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AXON. TCTC Holdings LLC raised its holdings in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 24 shares in the last quarter. Banque Transatlantique SA purchased a new stake in Axon Enterprise in the first quarter valued at approximately $31,000. Flaharty Asset Management LLC purchased a new stake in Axon Enterprise in the first quarter valued at approximately $33,000. Hemington Wealth Management lifted its position in Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 17 shares during the last quarter. Finally, Whipplewood Advisors LLC grew its stake in Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after buying an additional 27 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Down 0.5%

AXON opened at $569.51 on Thursday. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The business’s 50-day moving average price is $709.82 and its 200-day moving average price is $735.72. The company has a market cap of $44.94 billion, a P/E ratio of 140.62, a P/E/G ratio of 29.49 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.Axon Enterprise’s revenue was up 30.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Wall Street Zen downgraded Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Barclays dropped their price target on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. The Goldman Sachs Group decreased their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, UBS Group dropped their target price on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $810.71.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the firm’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director owned 1,416 shares of the company’s stock, valued at $1,065,596.64. This trade represents a 6.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $743.64, for a total transaction of $7,436,400.00. Following the completion of the transaction, the chief executive officer owned 3,043,982 shares in the company, valued at $2,263,626,774.48. The trade was a 0.33% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 52,041 shares of company stock valued at $36,794,077. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.